RxDoctor Payments Data

Mallareddy Maddula, MD

Nephrology · Stockton, CANPI 1487762647

Payments from drug & device makers

$4,254in general payments, 2019–2025

Across 204 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$957
  • Fresenius USA Marketing, Inc.$658
  • Otsuka America Pharmaceutical, Inc.$467
  • Amgen$428
  • GSK$244
  • Vifor Pharma, Inc.$242
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,01194%
  • Education$2436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,254 in reported general payments places this provider in the 65th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$519,608
Medicare patients
916
Services billed
3,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl53$159,654
AuryxiaFerric Citrate47$79,264
LokelmaSodium Zirconium Cyclosilicate74$68,958
VelphoroSucroferric Oxyhydroxide33$64,811
ProcritEpoetin Alfa72$55,349
FarxigaDapagliflozin Propanediol53$49,124
VeltassaPatiromer Calcium Sorbitex31$35,188
JardianceEmpagliflozin36$27,614
Sevelamer Carbonate99$26,879
JanuviaSitagliptin Phosphate21$24,930
OzempicSemaglutide20$17,766
Cinacalcet Hcl30$16,386
Calcium Acetate160$11,628
ClinolipidFat Emulsion/Olive/Soy/Phospho46$9,991
KerendiaFinerenone12$9,882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$957$118,082127 claims
Akebia Therapeutics IncAuryxia$112$79,26447 claims
Fresenius USA Marketing, Inc.Velphoro$658$64,81133 claims
Johnson & JohnsonProcrit$42$55,34972 claims
Boehringer IngelheimJardiance$67$27,61436 claims
Novo NordiskOzempic$37$17,76620 claims
BayerKerendia$32$9,88212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,341 nephrology providers in California.

Other nephrology in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →